Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.36 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311528 | 0.88 | CHRNA7 (0.46) | CHRNA7EZH2ALDH1A1NPC1RAB9A | |
| SCHEMBL6303374 | 0.85 | CHRNA7 (0.56) | CHRNA7EZH2ALDH1A1NPC1RAB9A | |
| SCHEMBL6310723 | 0.84 | CHRNA7 (0.46) | CHRNA7EZH2 | |
| SCHEMBL6306317 | 0.83 | CHRNA7 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL6305855 | 0.83 | HPGD (0.46) | CHRNA7EZH2ALDH1A1L3MBTL1 | |
| SCHEMBL6311196 | 0.83 | CHRNA7 (0.46) | CHRNA7EZH2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6306561 | 0.83 | CHRNA7 (0.46) | CHRNA7EZH2 | |
| SCHEMBL6303016 | 0.83 | KCNQ3 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL6310161 | 0.83 | CHRNA7 (0.44) | CHRNA7EZH2NPC1RAB9AL3MBTL1 | |
| SCHEMBL6303291 | 0.81 | CHRNA7 (0.42) | CHRNA7EZH2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-6852716-B2 | Substituted-aryl compounds for treatment of disease | PFIZER INC (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | NAT1, CYP7A1, CYP7B1 | CHRNB2 3625/4885CHRNB4 3743/4885CHRNA3 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.